Katsuhiko Mizuno et al., 2011-03: Toxicology study showing mebendazole and related benzimidazoles stimulate pro-inflammatory cytokine release from human monocytes through ERK1/2, offered as a mechanism for the liver injury reported with oral mebendazole.
The release of interleukin (IL)-8 and tumor necrosis factor (TNF) α from human monocytic THP-1 cells was significantly increased by treatment with MBZ, albendazole (ABZ), fenbendazole (FBZ), or oxibendazole (OBZ), but not by albendazole sulfoxide or praziquantel
Katsuhiko Mizuno et al., 2011-03: Toxicology study showing mebendazole and related benzimidazoles stimulate pro-inflammatory cytokine release from human monocytes through ERK1/2, offered as a mechanism for the liver injury reported with oral mebendazole. Study type: human THP-1 monocyte cell line. N: not applicable. Country: Japan (Kanazawa University). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: albendazole, fenbendazole, oxibendazole, albendazole sulfoxide, praziquantel, and MAPK inhibitors. PARTLY because the immune activation here is framed as the mechanism of an adverse drug reaction (hepatitis), not as antitumour immunity; it is the same finding read against the drug. Study type: lab.
